Skip to main content

Table 2 Survival analysis at final follow-up

From: Erlotinib versus gefitinib for brain metastases in Asian patients with exon 19 EGFR-mutant lung adenocarcinoma: a retrospective, multicenter study

Variable Erlotinib (n = 112) Gefitinib (n = 115) p - value
median PFS (months) 10.8(range, 0–21.3) 8.4(range, 0–20.5) 0.014*a
median OS (months) 28.3(range, 3.6–36.2) 25.0(range, 3.3–36.3) 0.033*a
Deaths, No. 50 67 0.04*b
 Age(y) 68.1 ± 8.73 67.7 ± 9.34 0.175c
 Sex    0.133b
 Female 30 49  
 Male 20 18  
 Smoking status    0.770d
 Never a smoker 30 44  
 Former smokers 13 10  
 Current smokers 7 13  
 Largest size of brain metastasis    0.326d
  ≤ 10 mm 11 10  
  > 10 mm 39 57  
 Number of brain metastasis    0.467d
  ≤ 3 22 25  
  > 3 28 42  
 ECOG performance status    0.177d
 0 6 8  
 1 15 30  
 2 21 22  
 3 8 7  
  1. *Statistically significant. aAnalysed using the log-rank test; bAnalysed using independent-samples t-test; cAnalysed using chi-squared test; dAnalysed using the Mann-Whitney test. PFS progression-free disease-free survival; OS overall survival; ECOG Eastern Cooperative Oncology Group